DORA PSI | Digital Object Repository at PSI

Export As:

Style

Style

Search Results 1 - 20 of 31

Sort

	Select Page
	Prostate-specific membrane antigen–targeted therapies for prostate cancer: towards improving therapeutic outcomes Corpetti, M., Müller, C., Beltran, H., de Bono, J., & Theurillat, J. P. (2024). Prostate-specific membrane antigen–targeted therapies for prostate cancer: towards improving therapeutic outcomes. European Urology, 85(3), 193-204. https://doi.org/10.1016/j.eururo.2023.11.018 Detailed Record Published Version Accepted Version
	Design and preclinical evaluation of a novel prostate-specific membrane antigen radioligand modified with a transthyretin binder Vaccarin, C., Mapanao, A. K., Deberle, L. M., Becker, A. E., Borgna, F., Marzaro, G., … Müller, C. (2024). Design and preclinical evaluation of a novel prostate-specific membrane antigen radioligand modified with a transthyretin binder. Cancers, 16(7), 1262 (13 pp.). https://doi.org/10.3390/cancers16071262 Detailed Record Published Version
	Albumin-binding and conventional PSMA ligands in combination with <sup>161</sup>Tb: biodistribution, dosimetry, and preclinical therapy Tschan, V. J., Busslinger, S. D., Bernhardt, P., Grundler, P. V., Zeevaart, J. R., Köster, U., … Müller, C. (2023). Albumin-binding and conventional PSMA ligands in combination with ¹⁶¹Tb: biodistribution, dosimetry, and preclinical therapy. Journal of Nuclear Medicine, 64(10), 1625-1631. https://doi.org/10.2967/jnumed.123.265524 Detailed Record Published Version Accepted Version
	Preclinical investigations to explore the difference between the diastereomers [<sup>177</sup>Lu]Lu-SibuDAB and [<sup>177</sup>Lu]Lu-RibuDAB toward prostate cancer therapy Borgna, F., Deberle, L. M., Busslinger, S. D., Tschan, V. J., Walde, L. M., Becker, A. E., … Müller, C. (2022). Preclinical investigations to explore the difference between the diastereomers [¹⁷⁷Lu]Lu-SibuDAB and [¹⁷⁷Lu]Lu-RibuDAB toward prostate cancer therapy. Molecular Pharmaceutics, 19(7), 2105-2114. https://doi.org/10.1021/acs.molpharmaceut.1c00994 Detailed Record Published Version Accepted Version
	[<sup>225</sup>Ac]Ac-SibuDAB for targeted alpha therapy of prostate cancer: preclinical evaluation and comparison with [<sup>225</sup>Ac]Ac-PSMA-617 Busslinger, S. D., Tschan, V. J., Richard, O. K., Talip, Z., Schibli, R., & Müller, C. (2022). [²²⁵Ac]Ac-SibuDAB for targeted alpha therapy of prostate cancer: preclinical evaluation and comparison with [²²⁵Ac]Ac-PSMA-617. Cancers, 14(22), 5651 (16 pp.). https://doi.org/10.3390/cancers14225651 Detailed Record Published Version
	Preclinical investigations using [<sup>177</sup>Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer Tschan, V. J., Borgna, F., Busslinger, S. D., Stirn, M., Monné Rodriguez, J. M., Bernhardt, P., … Müller, C. (2022). Preclinical investigations using [¹⁷⁷Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 49, 3639-3650. https://doi.org/10.1007/s00259-022-05837-2 Detailed Record Published Version
	Dosimetric analysis of the short-ranged particle emitter <sup>161</sup>Tb for radionuclide therapy of metastatic prostate cancer Bernhardt, P., Svensson, J., Hemmingsson, J., van der Meulen, N. P., Zeevaart, J. R., Konijnenberg, M. W., … Kindblom, J. (2021). Dosimetric analysis of the short-ranged particle emitter ¹⁶¹Tb for radionuclide therapy of metastatic prostate cancer. Cancers, 13(9), 2011 (13 pp.). https://doi.org/10.3390/cancers13092011 Detailed Record Published Version
	Biodistribution and dosimetry of a single dose of albumin-binding ligand [<sup>177</sup>Lu]Lu-PSMA-ALB-56 in patients with mCRPC Kramer, V., Fernández, R., Lehnert, W., Jiménez-Franco, L. D., Soza-Ried, C., Eppard, E., … Müller, C. (2021). Biodistribution and dosimetry of a single dose of albumin-binding ligand [¹⁷⁷Lu]Lu-PSMA-ALB-56 in patients with mCRPC. European Journal of Nuclear Medicine and Molecular Imaging, 48, 893-903. https://doi.org/10.1007/s00259-020-05022-3 Detailed Record Published Version
	Combined application of albumin-binding [<sup>177</sup>Lu]Lu-PSMA-ALB-56 and fast-cleared PSMA inhibitors: optimization of the pharmacokinetics Borgna, F., Deberle, L. M., Cohrs, S., Schibli, R., & Müller, C. (2020). Combined application of albumin-binding [¹⁷⁷Lu]Lu-PSMA-ALB-56 and fast-cleared PSMA inhibitors: optimization of the pharmacokinetics. Molecular Pharmaceutics, 17(6), 2044-2053. https://doi.org/10.1021/acs.molpharmaceut.0c00199 Detailed Record Published Version
	Albumin-binding PSMA radioligands: impact of minimal structural changes on the tissue distribution profile Deberle, L. M., Tschan, V. J., Borgna, F., Sozzi-Guo, F., Bernhardt, P., Schibli, R., & Müller, C. (2020). Albumin-binding PSMA radioligands: impact of minimal structural changes on the tissue distribution profile. Molecules, 25(11), 2542 (16 pp.). https://doi.org/10.3390/molecules25112542 Detailed Record Published Version
	Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity Deberle, L. M., Benešová, M., Umbricht, C. A., Borgna, F., Büchler, M., Zhernosekov, K., … Müller, C. (2020). Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Theranostics, 10(4), 1678-1693. https://doi.org/10.7150/thno.40482 Detailed Record Published Version
	Concentration‐dependent effects of dutasteride on prostate‐specific membrane antigen (PSMA) expression and uptake of <sup>177</sup>Lu‐PSMA‐617 in LNCaP cells Kranzbühler, B., Salemi, S., Umbricht, C. A., Deberle, L. M., Müller, C., Burger, I. A., … Eberli, D. (2019). Concentration‐dependent effects of dutasteride on prostate‐specific membrane antigen (PSMA) expression and uptake of ¹⁷⁷Lu‐PSMA‐617 in LNCaP cells. Prostate, 79(12), 1477-1483. https://doi.org/10.1002/pros.23868 Detailed Record Published Version
	Preclinical investigations and first-in-human application of <sup>152</sup>Tb-PSMA-617 for PET/CT imaging of prostate cancer Müller, C., Singh, A., Umbricht, C. A., Kulkarni, H. R., Johnston, K., Benešová, M., … Baum, R. P. (2019). Preclinical investigations and first-in-human application of ¹⁵²Tb-PSMA-617 for PET/CT imaging of prostate cancer. EJNMMI Research, 9(1), 68 (10 pp.). https://doi.org/10.1186/s13550-019-0538-1 Detailed Record Published Version
	Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer Müller, C., Umbricht, C. A., Gracheva, N., Tschan, V. J., Pellegrini, G., Bernhardt, P., … van der Meulen, N. P. (2019). Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 46(9), 1919-1930. https://doi.org/10.1007/s00259-019-04345-0 Detailed Record Published Version
	Targeted <sup>64</sup>Cu-labeled gold nanoparticles for dual imaging with positron emission tomography and optical imaging Pretze, M., van der Meulen, N. P., Wängler, C., Schibli, R., & Wängler, B. (2019). Targeted ⁶⁴Cu-labeled gold nanoparticles for dual imaging with positron emission tomography and optical imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 62(8), 471-482. https://doi.org/10.1002/jlcr.3736 Detailed Record Published Version
	First clinico-pathological evidence of a non PSMA-related uptake mechanism for <sup>68</sup>Ga-PSMA-11 in salivary glands Rupp, N. J., Umbricht, C. A., Pizzuto, D. A., Lenggenhager, D., Töpfer, A., Müller, J., … Burger, I. A. (2019). First clinico-pathological evidence of a non PSMA-related uptake mechanism for ⁶⁸Ga-PSMA-11 in salivary glands. Journal of Nuclear Medicine, 60(9), 1270-1276. https://doi.org/10.2967/jnumed.118.222307 Detailed Record Published Version Accepted Version
	Albumin-binding PSMA ligands: optimization of the tissue distribution profile Benešová, M., Umbricht, C. A., Schibli, R., & Müller, C. (2018). Albumin-binding PSMA ligands: optimization of the tissue distribution profile. Molecular Pharmaceutics, 15(3), 934-946. https://doi.org/10.1021/acs.molpharmaceut.7b00877 Detailed Record Published Version
	Structural analysis of small-molecule binding to the BAZ2A and BAZ2B Bromodomains Dalle Vedove, A., Spiliotopoulos, D., D'Agostino, V. G., Marchand, J. R., Unzue, A., Nevado, C., … Caflisch, A. (2018). Structural analysis of small-molecule binding to the BAZ2A and BAZ2B Bromodomains. ChemMedChem, 13(14), 1479-1487. https://doi.org/10.1002/cmdc.201800234 Detailed Record Published Version
	Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells Kranzbühler, B., Salemi, S., Umbricht, C. A., Müller, C., Burger, I. A., Sulser, T., & Eberli, D. (2018). Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells. Prostate, 78(10), 758-765. https://doi.org/10.1002/pros.23522 Detailed Record Published Version
	Design and preclinical evaluation of an albumin-binding PSMA ligand for <sup>64</sup>Cu-based PET imaging Umbricht, C. A., Benešová, M., Hasler, R., Schibli, R., van der Meulen, N. P., & Müller, C. (2018). Design and preclinical evaluation of an albumin-binding PSMA ligand for ⁶⁴Cu-based PET imaging. Molecular Pharmaceutics, 15(12), 5556-5564. https://doi.org/10.1021/acs.molpharmaceut.8b00712 Detailed Record Published Version